CoChat

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

Peck-Radosavljevic, Markus, Kudo, Masatoshi, Raoul, Jean-Luc, Lee, Han Chu, Decaens, Thomas, Heo, Jeong, Lin, Shi-Ming, Shan, Hong, Yang, Yefa, Bayh, Inga, Nakajima, Keiko, Cheng, Ann-Lii · 2018 · Journal of Clinical Oncology
Cited by 95

The DOI matches its Crossref record.

Abstract

4018 Background: TACE is often used to treat unresectable HCC (uHCC). However, there is no globally accepted consensus on the indication and definition of TACE failure. It is critical to reassess the risk/benefit of continuing TACE after failure as it may delay or prevent pts from receiving subsequent treatments. Methods: OPTIMIS, an international, prospective, observational study, enrolled pts with uHCC for whom a decision to treat with TACE was made at study entry. Practice patterns, safety, subsequent treatments, and outcomes data were collected. TACE ineligibility was defined and consistent with international and regional guidelines. Data were analyzed using descriptive statistical methods. Results: Overall, 1650 pts received TACE; 529 pts (32%) were BCLC stage C, 118 (7%) had extrahepatic spread, and 123 (7%) had portal vein thrombosis. At inclusion visit, 636 pts (39%) received TACE despite being TACE ineligible according to protocol-specified criteria. After first TACE, the proportion of pts with chronic liver function deterioration (worsening in CTCAE grade 30–90 days post TACE) ranged from 11% to 29% across assessed liver parameters. Complete and partial response rates to first TACE (N=1650) were 14% and 26%, respectively, which decreased by second (10% and 16%; n=1002), third (10% and 15%; n=580), and fourth (8% and 17%; n=338) TACE. Progressive disease rate increased by number of TACE procedures: 18%, 21%, 25%, and 27% for first, second, third, and fourth TACE, respectively. In total, only 507 pts (31%) became TACE ineligible during the study. Of those 507 pts, 47 (9%) received sorafenib at the time of TACE ineligibility and 460 (91%) received sorafenib later or not at all. Considerable imbalances between the 2 cohorts were observed; a propensity score analysis is planned to analyze overall survival from TACE ineligibility. Conclusions: These results indicate that real-world TACE use appears to deviate from treatment guidelines. This heterogeneity highlights the need for a globally accepted consensus on the indication and definition of TACE failure. These observations also indicate the importance of monitoring liver function in pts receiving TACE. Clinical trial information: NCT01933945.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.4018

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 95

Metadata

Authors
Peck-Radosavljevic, M., Kudo, M., Raoul, J.-L., Lee, H. C., Decaens, T., Heo, J., Lin, S.-M., Shan, H., Yang, Y., Bayh, I., Nakajima, K., & Cheng, A.-L.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
4018-4018
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2890402021
Cited by
95
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.4018
The paper
Peck-Radosavljevic, M., Kudo, M., Raoul, J.-L., Lee, H. C., Decaens, T., Heo, J., Lin, S.-M., Shan, H., Yang, Y., Bayh, I., Nakajima, K., & Cheng, A.-L. (2018). Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.4018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.